RU2015104001A - Комбинированная терапия для лечения глиобластомы - Google Patents
Комбинированная терапия для лечения глиобластомы Download PDFInfo
- Publication number
- RU2015104001A RU2015104001A RU2015104001A RU2015104001A RU2015104001A RU 2015104001 A RU2015104001 A RU 2015104001A RU 2015104001 A RU2015104001 A RU 2015104001A RU 2015104001 A RU2015104001 A RU 2015104001A RU 2015104001 A RU2015104001 A RU 2015104001A
- Authority
- RU
- Russia
- Prior art keywords
- patient
- vegf antibody
- chemotherapeutic agent
- effective amount
- glioblastoma
- Prior art date
Links
- 208000005017 glioblastoma Diseases 0.000 title claims abstract 11
- 238000011282 treatment Methods 0.000 title claims abstract 5
- 238000002648 combination therapy Methods 0.000 title 1
- 238000000034 method Methods 0.000 claims abstract 34
- 239000002246 antineoplastic agent Substances 0.000 claims abstract 15
- 229940127089 cytotoxic agent Drugs 0.000 claims abstract 15
- 230000004083 survival effect Effects 0.000 claims abstract 7
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical group O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 claims abstract 6
- 229960004964 temozolomide Drugs 0.000 claims abstract 6
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract 4
- 229960000397 bevacizumab Drugs 0.000 claims abstract 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims abstract 2
- 238000001802 infusion Methods 0.000 claims abstract 2
- 238000001959 radiotherapy Methods 0.000 claims abstract 2
- 238000002560 therapeutic procedure Methods 0.000 claims abstract 2
- 238000011394 anticancer treatment Methods 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 230000000973 chemotherapeutic effect Effects 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Radiology & Medical Imaging (AREA)
- Pathology (AREA)
- Biochemistry (AREA)
- Endocrinology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Oncology (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261680672P | 2012-08-07 | 2012-08-07 | |
| US61/680,672 | 2012-08-07 | ||
| US201261714438P | 2012-10-16 | 2012-10-16 | |
| US61/714,438 | 2012-10-16 | ||
| US201361760763P | 2013-02-05 | 2013-02-05 | |
| US61/760,763 | 2013-02-05 | ||
| PCT/US2013/053841 WO2014025813A1 (en) | 2012-08-07 | 2013-08-06 | Combination therapy for the treatment of glioblastoma |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2015104001A true RU2015104001A (ru) | 2016-09-27 |
Family
ID=48985869
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2015104001A RU2015104001A (ru) | 2012-08-07 | 2013-08-06 | Комбинированная терапия для лечения глиобластомы |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US20150148585A1 (OSRAM) |
| EP (2) | EP3446709A1 (OSRAM) |
| JP (4) | JP6464085B2 (OSRAM) |
| KR (3) | KR20150038593A (OSRAM) |
| CN (1) | CN104507498A (OSRAM) |
| AU (3) | AU2013299724A1 (OSRAM) |
| BR (1) | BR112015002681A2 (OSRAM) |
| CA (1) | CA2880767A1 (OSRAM) |
| HK (1) | HK1204993A1 (OSRAM) |
| IL (2) | IL237028B (OSRAM) |
| MX (1) | MX360189B (OSRAM) |
| RU (1) | RU2015104001A (OSRAM) |
| SG (1) | SG11201500903XA (OSRAM) |
| WO (1) | WO2014025813A1 (OSRAM) |
| ZA (1) | ZA201500811B (OSRAM) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20220053691A (ko) | 2013-03-15 | 2022-04-29 | 제넨테크, 인크. | Pd-1 및 pd-l1 관련 상태를 치료하기 위한 바이오마커 및 방법 |
| US10456470B2 (en) | 2013-08-30 | 2019-10-29 | Genentech, Inc. | Diagnostic methods and compositions for treatment of glioblastoma |
| US10617755B2 (en) | 2013-08-30 | 2020-04-14 | Genentech, Inc. | Combination therapy for the treatment of glioblastoma |
| SG11201606714TA (en) * | 2014-02-14 | 2016-09-29 | Andrew S Chi | Improved methods for the treatment of vascularizing cancers |
| JP6983511B2 (ja) * | 2014-04-25 | 2021-12-17 | ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア | 脳中の転移乳癌および他の癌を処置するための方法および組成物 |
| CA2946906A1 (en) * | 2014-05-07 | 2015-11-12 | Medimmune, Llc | Methods of using anti-ang2 antibodies |
| US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
| RU2715038C2 (ru) | 2014-07-11 | 2020-02-21 | Дженентек, Инк. | Антитела анти-pd-l1 и способы их диагностического применения |
| JP2017523776A (ja) | 2014-07-14 | 2017-08-24 | ジェネンテック， インコーポレイテッド | 膠芽腫の診断方法及びその治療用組成物 |
| KR20250057128A (ko) | 2015-12-30 | 2025-04-28 | 코디악 사이언시스 인코포레이티드 | 항체 및 이의 접합체 |
| BR112019026435A2 (pt) | 2017-06-12 | 2020-07-14 | Agios Pharmaceuticals, Inc. | métodos de tratamento de tumores cerebrais usando terapia de combinação |
| CN119280245A (zh) | 2017-06-12 | 2025-01-10 | 法国施维雅药厂 | 使用组合疗法治疗脑肿瘤的方法 |
| MX2020009152A (es) | 2018-03-02 | 2020-11-09 | Kodiak Sciences Inc | Anticuerpos de il-6 y constructos de fusion y conjugados de los mismos. |
| CN114786731A (zh) | 2019-10-10 | 2022-07-22 | 科达制药股份有限公司 | 治疗眼部病症的方法 |
Family Cites Families (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| WO1989006692A1 (en) | 1988-01-12 | 1989-07-27 | Genentech, Inc. | Method of treating tumor cells by inhibiting growth factor receptor function |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| CA2095633C (en) | 1990-12-03 | 2003-02-04 | Lisa J. Garrard | Enrichment method for variant proteins with altered binding properties |
| US20030206899A1 (en) | 1991-03-29 | 2003-11-06 | Genentech, Inc. | Vascular endothelial cell growth factor antagonists |
| US6582959B2 (en) | 1991-03-29 | 2003-06-24 | Genentech, Inc. | Antibodies to vascular endothelial cell growth factor |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| EP0940468A1 (en) | 1991-06-14 | 1999-09-08 | Genentech, Inc. | Humanized antibody variable domain |
| ATE348110T1 (de) | 1992-10-28 | 2007-01-15 | Genentech Inc | Hvegf rezeptor als vegf antagonist |
| US5635388A (en) | 1994-04-04 | 1997-06-03 | Genentech, Inc. | Agonist antibodies against the flk2/flt3 receptor and uses thereof |
| IL117645A (en) | 1995-03-30 | 2005-08-31 | Genentech Inc | Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration |
| SI1516628T1 (sl) | 1995-07-27 | 2013-10-30 | Genentech, Inc. | Stabilna izotonična liofilizirana proteinska formulacija |
| US6100071A (en) | 1996-05-07 | 2000-08-08 | Genentech, Inc. | Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production |
| SI1695985T1 (sl) | 1997-04-07 | 2011-06-30 | Genentech Inc | Postopki za tvorbo humaniziranih protiteles z naključno mutagenezo |
| US20020032315A1 (en) | 1997-08-06 | 2002-03-14 | Manuel Baca | Anti-vegf antibodies |
| WO1998045331A2 (en) | 1997-04-07 | 1998-10-15 | Genentech, Inc. | Anti-vegf antibodies |
| US6884879B1 (en) | 1997-04-07 | 2005-04-26 | Genentech, Inc. | Anti-VEGF antibodies |
| US6610833B1 (en) | 1997-11-24 | 2003-08-26 | The Institute For Human Genetics And Biochemistry | Monoclonal human natural antibodies |
| BR9813365A (pt) | 1997-12-05 | 2004-06-15 | Scripps Research Inst | Método para produção e humanização de um anticorpo monoclonal de rato |
| US6703020B1 (en) | 1999-04-28 | 2004-03-09 | Board Of Regents, The University Of Texas System | Antibody conjugate methods for selectively inhibiting VEGF |
| CA2393869A1 (en) | 1999-12-15 | 2001-06-21 | Genetech,Inc. | Shotgun scanning, a combinatorial method for mapping functional protein epitopes |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| ES2405944T3 (es) | 2000-11-30 | 2013-06-04 | Medarex, Inc. | Ácidos nucleicos que codifican las secuencias de inmunoglobulina humana reorganizadas a partir de ratones transcromoscómicos transgénicos zadas |
| CA2488441C (en) | 2002-06-03 | 2015-01-27 | Genentech, Inc. | Synthetic antibody phage libraries |
| US20050079574A1 (en) | 2003-01-16 | 2005-04-14 | Genentech, Inc. | Synthetic antibody phage libraries |
| RS20050885A (sr) | 2003-05-30 | 2008-04-04 | Genentech | Lečenje sa anti-vegf antitelima |
| WO2005044853A2 (en) | 2003-11-01 | 2005-05-19 | Genentech, Inc. | Anti-vegf antibodies |
| US20050106667A1 (en) | 2003-08-01 | 2005-05-19 | Genentech, Inc | Binding polypeptides with restricted diversity sequences |
| MXPA06011199A (es) | 2004-03-31 | 2007-04-16 | Genentech Inc | Anticuerpos anti-tgf-beta humanizados. |
| US7785903B2 (en) | 2004-04-09 | 2010-08-31 | Genentech, Inc. | Variable domain library and uses |
| US20060009360A1 (en) | 2004-06-25 | 2006-01-12 | Robert Pifer | New adjuvant composition |
| WO2007056441A2 (en) | 2005-11-07 | 2007-05-18 | Genentech, Inc. | Binding polypeptides with diversified and consensus vh/vl hypervariable sequences |
| WO2007064919A2 (en) | 2005-12-02 | 2007-06-07 | Genentech, Inc. | Binding polypeptides with restricted diversity sequences |
| AR060871A1 (es) | 2006-05-09 | 2008-07-16 | Genentech Inc | Union de polipeptidos con supercontigos optimizados |
| CN100592373C (zh) | 2007-05-25 | 2010-02-24 | 群康科技(深圳)有限公司 | 液晶显示面板驱动装置及其驱动方法 |
| SG175289A1 (en) * | 2009-04-20 | 2011-11-28 | Genentech Inc | Adjuvant cancer therapy |
| MX2012009554A (es) * | 2010-02-23 | 2012-11-23 | Hoffmann La Roche | Terapia anti-angiogenesis para el tratamiento del cancer ovarico. |
| AU2011293522B2 (en) * | 2010-08-24 | 2015-03-19 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Interleukin-13 receptor alpha 2 peptide-based brain cancer vaccines |
| US20120114638A1 (en) * | 2010-11-08 | 2012-05-10 | John Boylan | Combination therapy |
-
2013
- 2013-08-06 CN CN201380040940.7A patent/CN104507498A/zh active Pending
- 2013-08-06 KR KR20157005660A patent/KR20150038593A/ko not_active Ceased
- 2013-08-06 EP EP18178511.4A patent/EP3446709A1/en not_active Withdrawn
- 2013-08-06 KR KR1020197020608A patent/KR20190088571A/ko not_active Ceased
- 2013-08-06 SG SG11201500903XA patent/SG11201500903XA/en unknown
- 2013-08-06 KR KR1020187002046A patent/KR20180011356A/ko not_active Ceased
- 2013-08-06 EP EP13748450.7A patent/EP2882454B1/en not_active Revoked
- 2013-08-06 CA CA2880767A patent/CA2880767A1/en not_active Abandoned
- 2013-08-06 MX MX2015001627A patent/MX360189B/es active IP Right Grant
- 2013-08-06 BR BR112015002681A patent/BR112015002681A2/pt not_active Application Discontinuation
- 2013-08-06 WO PCT/US2013/053841 patent/WO2014025813A1/en not_active Ceased
- 2013-08-06 AU AU2013299724A patent/AU2013299724A1/en not_active Abandoned
- 2013-08-06 JP JP2015526648A patent/JP6464085B2/ja active Active
- 2013-08-06 RU RU2015104001A patent/RU2015104001A/ru not_active Application Discontinuation
- 2013-08-06 HK HK15105936.9A patent/HK1204993A1/xx unknown
-
2015
- 2015-02-01 IL IL237028A patent/IL237028B/en active IP Right Grant
- 2015-02-04 ZA ZA2015/00811A patent/ZA201500811B/en unknown
- 2015-02-06 US US14/616,505 patent/US20150148585A1/en not_active Abandoned
-
2016
- 2016-10-13 AU AU2016244262A patent/AU2016244262B2/en not_active Ceased
-
2017
- 2017-06-30 JP JP2017128609A patent/JP2018008946A/ja not_active Withdrawn
-
2018
- 2018-10-23 AU AU2018253461A patent/AU2018253461A1/en not_active Abandoned
- 2018-12-12 IL IL263661A patent/IL263661A/en unknown
-
2019
- 2019-04-18 JP JP2019079205A patent/JP2019147812A/ja active Pending
- 2019-04-29 US US16/397,104 patent/US20200086139A1/en not_active Abandoned
-
2021
- 2021-05-06 JP JP2021078365A patent/JP2021138704A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2014025813A1 (en) | 2014-02-13 |
| US20150148585A1 (en) | 2015-05-28 |
| ZA201500811B (en) | 2016-10-26 |
| KR20180011356A (ko) | 2018-01-31 |
| JP2015525798A (ja) | 2015-09-07 |
| KR20190088571A (ko) | 2019-07-26 |
| AU2018253461A1 (en) | 2018-11-15 |
| EP2882454B1 (en) | 2018-10-10 |
| BR112015002681A2 (pt) | 2018-08-28 |
| JP6464085B2 (ja) | 2019-02-06 |
| AU2016244262A1 (en) | 2016-11-03 |
| US20200086139A1 (en) | 2020-03-19 |
| AU2013299724A1 (en) | 2015-02-26 |
| KR20150038593A (ko) | 2015-04-08 |
| AU2016244262B2 (en) | 2018-07-26 |
| CN104507498A (zh) | 2015-04-08 |
| IL237028B (en) | 2019-03-31 |
| JP2021138704A (ja) | 2021-09-16 |
| EP2882454A1 (en) | 2015-06-17 |
| JP2019147812A (ja) | 2019-09-05 |
| JP2018008946A (ja) | 2018-01-18 |
| MX360189B (es) | 2018-10-24 |
| IL263661A (en) | 2019-01-31 |
| MX2015001627A (es) | 2015-06-23 |
| EP3446709A1 (en) | 2019-02-27 |
| HK1204993A1 (en) | 2015-12-11 |
| CA2880767A1 (en) | 2014-02-13 |
| SG11201500903XA (en) | 2015-03-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2015104001A (ru) | Комбинированная терапия для лечения глиобластомы | |
| RU2016109448A (ru) | Комбинированная терапия для лечения глиобластомы | |
| JP2016530280A5 (OSRAM) | ||
| JP2015525798A5 (OSRAM) | ||
| RU2019112029A (ru) | Применение комбинации антитела к pd-1 и ингибитора vegfr в изготовлении лекарственного средства для лечения злокачественных новообразований | |
| SI2691112T1 (en) | STABILITY FORMULATION PROTITELES FOR HUMAN PROGRAMMED DEPRESSOR RECEPTOR PD-1 AND RELATED HEALTH | |
| FI3227675T3 (fi) | Aktiviini-actrii-antagonisteja ja niiden käyttöjä myelodysplastisen oireyhtymän hoitamiseksi | |
| NZ723369A (en) | Plasma kallikrein binding proteins and uses thereof in treating hereditary angioedema | |
| JP2014503482A5 (OSRAM) | ||
| AR079903A1 (es) | Formulacion de anticuerpo y regimenes terapeuticos. envase farmaceutico. kit. | |
| JP2019163311A (ja) | 骨髄腫の治療 | |
| JP2018508462A5 (OSRAM) | ||
| RU2017108173A (ru) | Комбинированная терапия на основе антител, активирующих человеческий cd40, и антител к человеческому pd-l1 | |
| RU2012137498A (ru) | Фармацевтическая композиция для лечения и/или профилактики рака | |
| RU2013149282A (ru) | Комбинации и способы введения терапевтических агентов и комбинированная терапия | |
| RU2016136364A (ru) | Способы лечения или предупреждения астмы посредством введения антагониста il-4r | |
| AR086238A1 (es) | FORMULACION PARA ANTICUERPO ANTI-a4b7 | |
| RU2017134443A (ru) | Способ лечения с применением традипитанта | |
| RU2011144312A (ru) | БИСПЕЦИФИЧЕСКИЕ АНТИ-ErbB-3/АНТИ-С-МЕТ АНТИТЕЛА | |
| HRP20250472T1 (hr) | Režim doziranja antitijela anti-alpha4beta7 | |
| JP2018515493A5 (OSRAM) | ||
| RU2018146886A (ru) | Пути терапевтического применения ингибитора c-raf | |
| JP2013538796A5 (OSRAM) | ||
| AR091462A1 (es) | Anticuerpos anti-pcsk9, formulaciones, dosificacion y metodos de uso | |
| RU2011142183A (ru) | Средство для лечения ревматоидного артрита |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20180207 |